Macular Degeneration (AMD)



The Potential Role of Dietary Antioxidant Capacity on Age-Related Macular Degeneration


Condition:   Age Related Macular Degeneration
Intervention:  
Sponsor:   Hacettepe University
Completed


A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration


Condition:   Neovascular Age-Related Macular Degeneration
Interventions:   Drug: GB-102;   Drug: Aflibercept
Sponsor:   Graybug Vision
Recruiting


Dark Adaptation in Participants With Age-Related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:  
Sponsor:   National Eye Institute (NEI)
Enrolling by invitation


Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator


Condition:   Age-related Macular Degeneration
Intervention:  
Sponsor:   University of Alabama at Birmingham
Not yet recruiting


Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal


Condition:   Age-Related Macular Degeneration
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Completed


Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration


Condition:   Macular Degeneration
Intervention:   Device: Ocusweep system
Sponsor:   Turku University Hospital
Enrolling by invitation


Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration


Condition:   Neovascular Age-related Macular Degeneration
Intervention:   Biological: TK001
Sponsor:   Jiangsu T-Mab Biopharma Co.,Ltd
Recruiting


Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye


Condition:   Macular Degeneration
Intervention:   Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Sponsor:   Bayer
Active, not recruiting


A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Drug: DE-122
Sponsor:   Santen Inc.
Completed


Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan


Condition:   Wet Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Completed


Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)


Condition:   Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Recruiting


Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration


Condition:   Macular Degeneration
Interventions:   Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
Sponsor:   Allergan
Active, not recruiting


A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Interventions:   Drug: DE-120;   Drug: Aflibercept
Sponsor:   Santen Inc.
Completed


Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration


Condition:   Wet Macular Degeneration
Intervention:   Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Sponsors:   Bayer;   Regeneron Pharmaceuticals
Active, not recruiting


Macular Degeneration and Aging Study


Condition:   Age-related Macular Degeneration
Interventions:   Behavioral: Preventive Problem-Solving Training;   Behavioral: Life and Health Review
Sponsors:   University of Rochester;   Dartmouth-Hitchcock Medical Center;   Association for the Blind and Visually Impaired
Active, not recruiting


A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).


Condition:   Neovascular Macular Degeneration
Intervention:   Drug: Aflibercept
Sponsors:   University of Nebraska;   Regeneron Pharmaceuticals
Completed


A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Drug: DE-120
Sponsor:   Santen Inc.
Completed



Proton Radiation Therapy for Macular Degeneration


Condition:   Age-Related Macular Degeneration
Intervention:   Radiation: Proton radiation
Sponsor:   University of Florida
Active, not recruiting


Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)


Condition:   Age-related Macular Degeneration
Interventions:   Drug: Omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3;   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   National Eye Institute (NEI)
Active, not recruiting


Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration


Conditions:   Age-Related Macular Degeneration;   Macular Degeneration
Interventions:   Drug: Intravitreal Aflibercept Injection More;   Drug: Intravitreal Aflibercept Injection Less
Sponsors:   MidAtlantic Retina;   Regeneron Pharmaceuticals
Completed


A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration


Condition:   Macular Degeneration
Intervention:   Drug: ALG 1001
Sponsor:   Allegro Ophthalmics, LLC
Completed


Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration


Condition:   Age Related Macular Degeneration and Stargartd
Intervention:   Other: intravitreal injection of autologous bone marrow stem cells
Sponsor:   University of Sao Paulo
Completed


12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)


Condition:   Macular Degeneration
Intervention:   Drug: pazopanib eye drops
Sponsor:   GlaxoSmithKline
Terminated


Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)


Condition:   Age Related Macular Degeneration
Intervention:   Drug: Subretinally injected RetinoStat
Sponsor:   Oxford BioMedica
Completed

Refine Your Search Advanced Search